Research Background

This study aims to establish a human infection model (CHIM) to evaluate whether oral administration of Trichuris trichiura eggs can safely induce infection. Historically, there have been few attempts to deliberately infect humans, creating a need for a novel platform for early efficacy assessment.

Clinical Design

In a Phase 1 trial, healthy adult volunteers will be enrolled and administered varying doses of eggs. The primary objectives are to assess safety, tolerability, and to identify the optimal dose that consistently produces infection. Dose escalation will proceed in a stepwise manner, with infection status confirmed by stool testing.

Current Therapeutic Landscape and Differentiation

Trichuris trichiura infection is currently treated with anthelmintics such as albendazole, but concerns about reinfection risk and emerging drug resistance persist. The CHIM enables rapid early‑stage evaluation of novel therapeutics or vaccine candidates, offering a differentiation from existing treatment approaches.

Industry Impact

A successful CHIM provides pharmaceutical and biotech companies with a platform to rapidly assess candidate molecules not only for Trichuris trichiura but also for other intestinal parasitic diseases. Even if specific programs fail, the infection model remains a valuable research infrastructure that can be jointly leveraged by academia and industry. Consequently, investors should monitor this early‑stage infrastructure development.